BackgroundTriple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression. This is an aggressive malignancy with a poor prognosis despite the high rates of response to chemotherapy. The aim of this study is to determine the clinicopathological, therapeutic features and outcomes associated with this type of breast cancer.MethodsThis is a retrospective study of confirmed triple negative breast cancer females collected at the National institute of oncology of Rabat in Morocco, between January 2007 and December 2008. Epidemiological, clinical, histological, therapeutic and evolutive data were analyzed. OS and DFS rates were estimated by Kaplan-Meier analysis.ResultsA total of one 152 patients with breast cancer, were identified as having triple-negative breast cancer (16,5%). The median age at diagnosis was 46 years. 130 patients (86%) had infiltrating ductal carcinoma and thirteen had medullar carcinoma (9%). 84 cases (55%) were grade III Scarff-Bloom-Richardson (SBR). 48 % had positive lymph nodes, and 5 % had distant metastases at diagnosis. According TNM staging, 12 patients (8%) had stage I, 90 patients (60%) had stage II and the 43(28%) had stage III. 145 patients received surgery. 41 (28%) had conservative surgery and 104 (72%) received radical mastectomy with axillary lymph nodes dissection. 14 patients with advanced tumors or inflammatory breast cancer have received neoadjuvant chemotherapy and four patients (28%) had complete pathologic response. From 131 patients how received adjuvant chemotherapy, 99 patients (75,5%) had Anthracycline based chemotherapy) and 27 patients (20,6%) had sequential Anthracycline and docetaxel,. Seven patients with metastatic disease received anthracycline-based regimen in the first line metastatic chemotherapy. The median follow-up time was 46 months (range 6,1 -60 months). Overall survival at 5 years for all patients was 76,5%.ConclusionThese results suggest that most TNBC characteristics in Moroccan patients are in accordance with literature data, especially concerning young age at diagnosis high grade tumors, advanced stage at diagnosis, and short time to relapse. Although the high response rate to chemotherapy, the overall prognosis of this subset of tumors remains poor.

Background: Germ cell tumours are uncommon in aged man. We present a rare case of metastatic seminoma of the testis associated with liver and renal insufficiencies in a 78-years-old man managed successfully with carboplatin based chemotherapy.

Primary cardiac sarcoma is a rare aggressive entity. It constitutes the second most common type of primary cardiac neoplasms. Its management has largely been guided by small retrospective series with a median survival of 6 months. Here, we discuss a unique case of 8-year survival cardiac leiomyosarcoma managed by surgical and adjuvant therapy.

Introduction Primary laryngeal lymphomas are exceedingly rare. Only about a hundred cases have been reported. They consist mainly of non-Hodgkin lymphoma, especially of diffuse large B-cell lymphoma and mucosa-associated lymphoid tissue. We report the first case of a primary laryngeal mantle cell lymphoma. Case presentation We report a case of a primary mantle cell lymphoma of the larynx in a 70-year-old North African non-smoker male. We present a detailed report of his clinical and paraclinical data as well as treatment options. Conclusions Mantle cell lymphoma is a very aggressive lymphoma subset associated with poor prognosis. Laryngeal mantle cell lymphoma is exceedingly rare. To the best of our knowledge, this is the first case to ever be reported.

Le carcinosarcome du sein souvent appelé carcinome métaplasique du sein, est une tumeur maligne rare composée de deux lignées cellulaires distinctes, il est décrit comme un cancer du sein de type canalaire avec un composant de type sarcome. Il représente 0,08-0.2% de toutes les tumeurs malignes du sein. Il s'agit d'une étude rétrospective étalée sur un an, huit cas des carcinosarcomes mammaires ont été colligés à l'Institut national d'oncologie au Maroc durant l'année 2007. La médiane d’âge était de 49,5 ans, toutes les tumeurs étaient de haut grade, cliniquement 5 cas ont été classé t2 ou t3, et 3 cas classé sein localement avancé. Le traitement envisagé était basé sur une chirurgie mammaire suivie d'une radiothérapie et d'une chimiothérapie pour les cas adjuvants, l'envahissement ganglionnaire a été noté dans un cas, les récepteurs œstrogèniques sont négatifs, alors que les récepteurs progesteroniques sont positifs dans 4 cas, l'expression d'Her2 est absente dans tous les cas, le traitement des carcinosarcomes mammaires métastatiques était basé sur une chimiothérapie palliative. A 20 mois de médiane follow-up, la survie sans progression(SSP) pour le groupe entier est de 62,5%. Dans la limite de ce suivi, une rechute locorégionale a été détectée dans un cas, les deux patientes métastatiques sont décédées. Le carcinosarcome du sein est un sous-type rare du cancer du sein qui a un profil particulier et agressif, il a souvent un caractère triple négatif. Il est nécessaire de développer d'autres voies de recherche comme cibler le Récepteur HER1/EGFR.